Lurbinectedin

Overview

Lurbinectedin is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4297516).

API suppliers (8)

Suppliers of Lurbinectedin backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Pharma Mar, S.A.Spain1 active DMF
• Ono Pharmaceutical Co., Ltd.Japan1 active DMF
• Natco PharmaIndia1 active DMF
• BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTDChina1 active DMF
• XILING LAB CO LTDChina1 active DMF
• MSN Laboratories Private LimitedIndia1 active DMF
• CHONGQING CARELIFE PHARMACEUTICAL CO LTDChina1 active DMF
• APICORE US LLCUnited States1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Lurbinectedin expires 29 May 2040 and exclusivity 2 Oct 2028. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

[(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate

Canonical SMILES

CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O

InChIKey

YDDMIZRDDREKEP-HWTBNCOESA-N